Stock DNA
Commodity Chemicals
INR 790 Cr (Micro Cap)
8.00
39
0.64%
-0.40
9.46%
0.76
Total Returns (Price + Dividend) 
Latest dividend: 3 per share ex-dividend date: Sep-19-2025
Risk Adjusted Returns v/s 
Returns Beta
News

Sr.Rayala.Hypo Sees Revision in Market Evaluation Amid Challenging Financial Trends
Sr.Rayala.Hypo, a microcap player in the Commodity Chemicals sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a period marked by subdued sales growth, negative financial trends, and bearish technical signals, all contributing to a more cautious market perspective.
Read More
Sree Rayalaseema Hi-Strength Hypo Q2 2025 Financial Trend Shows Negative Shift Amidst Record Sales
Sree Rayalaseema Hi-Strength Hypo, a key player in the Commodity Chemicals sector, has experienced a notable change in its financial trend for the quarter ending September 2025. Despite recording its highest quarterly net sales at ₹182.39 crores and cash and cash equivalents peaking at ₹413.48 crores, the company’s overall financial trend shifted from flat to negative, reflecting a complex performance landscape.
Read MoreAre Sr.Rayala.Hypo latest results good or bad?
The latest financial results for Sree Rayalaseema Hi-Strength Hypo indicate a complex operational landscape. In the quarter ending September 2025, the company reported a net profit of ₹23.29 crores, reflecting a quarter-on-quarter increase of 3.93%. This modest growth in net profit was supported by a 1.18% rise in revenue, which reached ₹182.39 crores, marking the highest quarterly revenue on record. However, this revenue growth contrasts sharply with the year-on-year performance, as net profit declined by 7.94% compared to the same quarter last year. The operating margin for the company contracted to 14.78%, down from 15.49% in the previous quarter and significantly lower than the 17.00% achieved in the same quarter last year. This decline in operating margin, which reflects a compression of 222 basis points year-on-year, suggests that the company is facing challenges in maintaining pricing power amid ris...
Read More Announcements 
Report On Special Window
13-Jan-2026 | Source : BSESubmission of report issued by Companys RTA with regard to Special window for re- lodgement of transfer requests
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
07-Jan-2026 | Source : BSESubmission of certificate under regulation 74(5) of SEBI(DP) Regulations 2018 for third quarter ending 31.12.2025.
Closure of Trading Window
25-Dec-2025 | Source : BSEIntimation of closure of trading window
Corporate Actions 
No Upcoming Board Meetings
Sree Rayalaseema Hi-Strength Hypo Ltd has declared 30% dividend, ex-date: 19 Sep 25
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 3 Schemes (0.01%)
Held by 5 FIIs (0.06%)
Gowri Gopal Hospitals Private Limited (21.8%)
None
26.33%
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 1.18% vs 12.33% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is 3.93% vs 1.91% in Jun 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 7.02% vs -30.32% in Sep 2024
Growth in half year ended Sep 2025 is 5.51% vs 2.64% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'24
YoY Growth in nine months ended Dec 2024 is -31.89% vs -42.31% in Dec 2023
YoY Growth in nine months ended Dec 2024 is 10.20% vs -28.54% in Dec 2023
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -26.35% vs -47.52% in Mar 2024
YoY Growth in year ended Mar 2025 is 10.76% vs -48.80% in Mar 2024